HUP0004454A2 - APO B szekréciós/MTP inhibitor hatású gyógyszerkészítmények - Google Patents

APO B szekréciós/MTP inhibitor hatású gyógyszerkészítmények

Info

Publication number
HUP0004454A2
HUP0004454A2 HU0004454A HUP0004454A HUP0004454A2 HU P0004454 A2 HUP0004454 A2 HU P0004454A2 HU 0004454 A HU0004454 A HU 0004454A HU P0004454 A HUP0004454 A HU P0004454A HU P0004454 A2 HUP0004454 A2 HU P0004454A2
Authority
HU
Hungary
Prior art keywords
secretion
apo
apolipoprotein
transfer protein
pharmaceutical compositions
Prior art date
Application number
HU0004454A
Other languages
English (en)
Inventor
Mary Anne Hickman
Kristin Marie Lundy
Bradley Paul Morgan
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of HU0004454D0 publication Critical patent/HU0004454D0/hu
Publication of HUP0004454A2 publication Critical patent/HUP0004454A2/hu
Publication of HUP0004454A3 publication Critical patent/HUP0004454A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány tárgya gyógyászati készítmények táplálékfelvételcsökkentésére, amelyek apolipoprotein B (apo B) kiválasztást ésmikroszóma triglicerid transzfer fehérjét (MTP) gátló hatóanyagottartalmaznak. A gyógyászati készítmények az apolipoprotein B (apo B)kiválaszt és mikroszóma triglicerid transzfer fehérjét (MTP) gátlóhatóanyag mellett egy elhízás elleni hatóanyagot is tartalmazhatnak. Atalálmány tárgya továbbá egységcsomag, amelynek alkotórészei:apolipoprotein B kiválasztás/mikroszomális triglicerid transzferfehérje gátló hatóanyag és egy gyógyászatilag elfogadható vivőanyag,töltőanyag vagy hígítóanyag az első dózisegységben; egy elhízás ellenihatóanyag és egy gyógyászatilag elfogadható vivőanyag, töltőanyag vagyhígítóanyag a második dózisegységben; továbbá egy tároló csomagolás. Ó
HU0004454A 1999-11-10 2000-11-09 Pharmaceutical compositions as apo b secretion/mtp inhibitors HUP0004454A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16451399P 1999-11-10 1999-11-10

Publications (3)

Publication Number Publication Date
HU0004454D0 HU0004454D0 (hu) 2001-01-29
HUP0004454A2 true HUP0004454A2 (hu) 2001-10-28
HUP0004454A3 HUP0004454A3 (en) 2004-04-28

Family

ID=22594839

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0004454A HUP0004454A3 (en) 1999-11-10 2000-11-09 Pharmaceutical compositions as apo b secretion/mtp inhibitors

Country Status (11)

Country Link
EP (1) EP1099438A3 (hu)
JP (1) JP2001181209A (hu)
KR (1) KR100439384B1 (hu)
AU (1) AU777542B2 (hu)
CA (1) CA2325282C (hu)
CO (1) CO5271688A1 (hu)
HU (1) HUP0004454A3 (hu)
IL (1) IL139449A0 (hu)
NZ (1) NZ508061A (hu)
PE (1) PE20010679A1 (hu)
ZA (1) ZA200006417B (hu)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6825209B2 (en) 2002-04-15 2004-11-30 Research Triangle Institute Compounds having unique CB1 receptor binding selectivity and methods for their production and use
EA010369B1 (ru) 2004-02-04 2008-08-29 Пфайзер Продактс Инк. Замещенные хинолиновые соединения
JP2008542255A (ja) * 2005-05-27 2008-11-27 ファイザー・プロダクツ・インク 肥満症の治療または体重減量の維持のためのカンナビノイド−１受容体アンタゴニストおよびミクロソームトリグリセリド輸送タンパク質阻害物質の併用
WO2008090198A1 (en) * 2007-01-25 2008-07-31 Janssen Pharmaceutica Nv Use of mtp inhibitors for increasing levels of satiety hormones
KR102569494B1 (ko) 2014-07-15 2023-08-21 이슘 리서치 디벨롭먼트 컴퍼니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. Cd44의 단리된 폴리펩타이드 및 이의 사용

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1893492A (en) * 1991-04-17 1992-11-17 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US5474993A (en) * 1994-06-14 1995-12-12 Sterling Winthrop, Inc. Lactam inhibitors of cholesterol esterase
EP0832069B1 (en) * 1995-06-07 2003-03-05 Pfizer Inc. BIPHENYL-2-CARBOXYLIC ACID-TETRAHYDRO-ISOQUINOLIN-6-YL AMIDE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS INHIBITORS OF MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN AND/OR APOLIPOPROTEIN B (Apo B) SECRETION
PL329739A1 (en) * 1996-04-30 1999-04-12 Pfizer Methods of and intermediate compounds for obtaining [2-(2h-[1.2.4] - triazol-3-ylmethyl)-1,2,3,4-tetrahydroisoquinolin-6-yl] amide of 4'-trifluoromethylbiphenyl-2-carboxylic acid
US5883109A (en) * 1996-07-24 1999-03-16 Bristol-Myers Squibb Company Method for lowering serum lipid levels employing an MTP inhibitor in combination with another cholesterol lowering drug
US6121283A (en) * 1996-11-27 2000-09-19 Pfizer Inc Apo B-secretion/MTP inhibitory amides
US5968950A (en) * 1997-06-23 1999-10-19 Pfizer Inc Apo B-secretion/MTP inhibitor hydrochloride salt
IL133201A0 (en) * 1998-12-04 2001-03-19 Pfizer Prod Inc Lowering blood levels of lipoproten (a)

Also Published As

Publication number Publication date
PE20010679A1 (es) 2001-06-30
KR100439384B1 (ko) 2004-07-09
CA2325282A1 (en) 2001-05-10
ZA200006417B (en) 2002-05-08
AU7151900A (en) 2001-05-17
HU0004454D0 (hu) 2001-01-29
EP1099438A3 (en) 2003-03-19
CA2325282C (en) 2005-12-06
NZ508061A (en) 2002-04-26
HUP0004454A3 (en) 2004-04-28
AU777542B2 (en) 2004-10-21
CO5271688A1 (es) 2003-04-30
IL139449A0 (en) 2001-11-25
KR20010051509A (ko) 2001-06-25
EP1099438A2 (en) 2001-05-16
JP2001181209A (ja) 2001-07-03

Similar Documents

Publication Publication Date Title
EE9800173A (et) Gonadotropiini riliisinghormooni antagonistid
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
TR200502189T1 (tr) Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
AU2002360462A1 (en) Compositions containing both sedative and non-sedative antihistamines
ATE387430T1 (de) Verbindungen und zusammensetzungen zur abgabe aktiver wirkstoffe
HUP0302319A2 (hu) Gyógyszerkészítmények gyógyászati hatóanyagok szájon át történő bejuttatására
ATE311373T1 (de) Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
BR0306928A (pt) Composições farmacêuticas estáveis compreendendo inibidores de enzimas conversoras de angiotensina (ace)
GB9721746D0 (en) Compositions
MXPA05005781A (es) Combinacion de ibuprofeno y oxicodona para alivio de dolor agudo.
MY141012A (en) Combination comprising an at1-receptor antagonist and an insulin secretion enhancer or an insulin sensitiser
ATE324112T1 (de) Topische behandlung bei der mastalgie
HUP0004454A2 (hu) APO B szekréciós/MTP inhibitor hatású gyógyszerkészítmények
WO2002015892A3 (en) Combination comprising an insulin secretion enhancer and an active ingredient selected from hmg-co-a reductase inhibitors and ace inhibitors
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
BR0209155A (pt) Tablete farmacêutico tendo um teor de api elevado
MX2009006699A (es) Composicion y metodo para preparar tabletas oralmente disgregantes que contienen una alta dosis de ingredientes farmaceuticamente activos.
ATE213643T1 (de) Ciclosporin formulierung
MXPA03010672A (es) Composicion para el tratamiento regenerativo de enfermedades del cartilago.
GB9930768D0 (en) Composition
EP1099439A3 (en) Use of apo B secretion/MTP inhibitors
HUP0300576A2 (hu) Érkárosító hatású, osztott dózisú gyógyászati készítmény
MXPA04005033A (es) Composicion farmaceutica que comprende una combinacion de metformina y acido 4-oxobutanoico y el uso de la misma para el tratamiento contra diabetes.